Relationship between Invasive and Non-Invasive Hemodynamic Measures in Experimental Pulmonary Hypertension

Author(s): Vicente Benavides-Córdoba*, Mauricio Palacios Gómez

Journal Name: Current Respiratory Medicine Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Animal models have been used to understand the pathophysiology of pulmonary hypertension, to describe the mechanisms of action and to evaluate promising active ingredients. The monocrotaline-induced pulmonary hypertension model is the most used animal model. In this model, invasive and non-invasive hemodynamic variables that resemble human measurements have been used. Aim: To define if non-invasive variables can predict hemodynamic measures in the monocrotaline-induced pulmonary hypertension model.

Materials and Methods: Twenty 6-week old male Wistar rats weighing between 250-300g from the bioterium of the Universidad del Valle (Cali - Colombia) were used in order to establish that the relationships between invasive and non-invasive variables are sustained in different conditions (healthy, hypertrophy and treated). The animals were organized into three groups, a control group who was given 0.9% saline solution subcutaneously (sc), a group with pulmonary hypertension induced with a single subcutaneous dose of Monocrotaline 30 mg/kg, and a group with pulmonary hypertension with 30 mg/kg of monocrotaline treated with Sildenafil. Right ventricle ejection fraction, heart rate, right ventricle systolic pressure and the extent of hypertrophy were measured. The functional relation between any two variables was evaluated by the Pearson correlation coefficient.

Results: It was found that all correlations were statistically significant (p <0.01). The strongest correlation was the inverse one between the RVEF and the Fulton index (r = -0.82). The Fulton index also had a strong correlation with the RVSP (r = 0.79). The Pearson correlation coefficient between the RVEF and the RVSP was -0.81, meaning that the higher the systolic pressure in the right ventricle, the lower the ejection fraction value. Heart rate was significantly correlated to the other three variables studied, although with relatively low correlation.

Conclusion: The correlations obtained in this study indicate that the parameters evaluated in the research related to experimental pulmonary hypertension correlate adequately and that the measurements that are currently made are adequate and consistent with each other, that is, they have good predictive capacity.

Keywords: Animal models, hemodynamic measures, left ventricle, MCT, pulmonary hypertension, right ventricle hypertrophy.

[1]
Guignabert C, Dorfmüller P. pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med 2017; 38(5): 571-84.
[http://dx.doi.org/10.1055/s-0037-1606214] [PMID: 29032561]
[2]
Galiè N, Humbert M, Vachiery JL, et al. ESC scientific document group. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37(1): 67-119.
[http://dx.doi.org/10.1093/eurheartj/ehv317] [PMID: 26320113]
[3]
Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015; 24(138): 621-9.
[http://dx.doi.org/10.1183/16000617.0063-2015] [PMID: 26621976]
[4]
Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012; 302(4): L363-9.
[http://dx.doi.org/10.1152/ajplung.00212.2011] [PMID: 21964406]
[5]
Anderson DC, Kodukula K. Biomarkers in pharmacology and drug discovery. Biochem Pharmacol 2014; 87(1): 172-88.
[http://dx.doi.org/10.1016/j.bcp.2013.08.026] [PMID: 24001556]
[6]
Rafikova O, Meadows ML, Kinchen JM, et al. metabolic changes precede the development of pulmonary hypertension in the monocrotaline exposed rat lung. PLoS One 2016; 11(3): e0150480
[http://dx.doi.org/10.1371/journal.pone.0150480] [PMID: 26937637]
[7]
Nakai G, Shimura D, Uesugi K, et al. Pyruvate dehydrogenase activation precedes the down-regulation of fatty acid oxidation in monocrotaline-induced myocardial toxicity in mice. Heart Vessels 2019; 34(3): 545-55.
[http://dx.doi.org/10.1007/s00380-018-1293-3] [PMID: 30386918]
[8]
Kay JM. Crotalaria (Monocrotaline) pulmonary hypertension: The fiftieth anniversary. Chest 2017; 152(6): 1117-9.
[http://dx.doi.org/10.1016/j.chest.2017.06.013] [PMID: 28642105]
[9]
Brown MB, Neves E, Long G, et al. High-intensity interval training, but not continuous training, reverses right ventricular hypertrophy and dysfunction in a rat model of pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 2017; 312(2): R197-210.
[http://dx.doi.org/10.1152/ajpregu.00358.2016] [PMID: 27784688]
[10]
Ma Z, Mao L, Rajagopal S. Hemodynamic characterization of rodent models of pulmonary arterial hypertension. J Vis Exp 2016. (110):
[11]
Fujimoto Y, Urashima T, Kawachi F, et al. Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats. J Thorac Cardiovasc Surg 2017; 154(5): 1742-1753.e8.
[http://dx.doi.org/10.1016/j.jtcvs.2017.06.053] [PMID: 28755882]
[12]
Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 2013; 62(25)(Suppl.): D22-33.
[http://dx.doi.org/10.1016/j.jacc.2013.10.027] [PMID: 24355638]
[13]
Gage GJ, Kipke DR, Shain W. Whole animal perfusion fixation for rodents. J Vis Exp M 2012. (65):
[14]
Brenes F, Harris S, Paz MO, Petrovic LM, Scheuer PJ. PLP fixation for combined routine histology and immunocytochemistry of liver biopsies. J Clin Pathol 1986; 39(4): 459-63.
[http://dx.doi.org/10.1136/jcp.39.4.459] [PMID: 3009559]
[15]
National Research Council Committee for the update of the guide for the care and use of laboratory a. the national academies collection: reports funded by National Institutes of Health. In: th, editor guide for the care and use of laboratory animals Washington (DC): National Academies Press (US) National Academy of Sciences 2011.
[16]
Fujita N, Yamasaki N, Eto K, Asaeda M, Kuwahara W, Imagita H. Oxygen therapy may worsen the survival rate in rats with monocrotaline-induced pulmonary arterial hypertension. PLoS One 2018; 13(9): e0204254
[http://dx.doi.org/10.1371/journal.pone.0204254] [PMID: 30235299]
[17]
Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006; 291(5): H2424-30.
[http://dx.doi.org/10.1152/ajpheart.00369.2006] [PMID: 16731643]
[18]
Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008; 117(11): 1436-48.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.653576] [PMID: 18347220]
[19]
Dohi K, Onishi K, Gorcsan J III, et al. Role of radial strain and displacement imaging to quantify wall motion dyssynchrony in patients with left ventricular mechanical dyssynchrony and chronic right ventricular pressure overload. Am J Cardiol 2008; 101(8): 1206-12.
[http://dx.doi.org/10.1016/j.amjcard.2007.11.077] [PMID: 18394460]
[20]
Pritts CD, Pearl RG. Anesthesia for patients with pulmonary hypertension. Curr Opin Anaesthesiol 2010; 23(3): 411-6.
[http://dx.doi.org/10.1097/ACO.0b013e32833953fb] [PMID: 20386437]
[21]
Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012; 7(8): e43433
[http://dx.doi.org/10.1371/journal.pone.0043433] [PMID: 22912874]
[22]
Bae HK, Lee H, Kim KC, Hong YM. The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure. Korean J Pediatr 2016; 59(6): 262-70.
[http://dx.doi.org/10.3345/kjp.2016.59.6.262] [PMID: 27462355]
[23]
Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 279-313.
[http://dx.doi.org/10.1007/978-3-662-45805-1_12] [PMID: 24092345]
[24]
Ghofrani HA, Galiè N, Grimminger F, et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369(4): 330-40.
[http://dx.doi.org/10.1056/NEJMoa1209655] [PMID: 23883378]
[25]
Nishiyama T. Changes in heart rate variability during anaesthesia induction using sevoflurane or isoflurane with nitrous oxide. Anaesthesiol Intensive Ther 2016; 48(4): 248-51.
[http://dx.doi.org/10.5603/AIT.a2016.0041] [PMID: 27689429]
[26]
Homberg JR, Wöhr M, Alenina N. Comeback of the rat in biomedical research. ACS Chem Neurosci 2017; 8(5): 900-3.
[http://dx.doi.org/10.1021/acschemneuro.6b00415] [PMID: 28182397]
[27]
Meyza KZ, Bartal IB, Monfils MH, Panksepp JB, Knapska E. The roots of empathy: through the lens of rodent models. Neurosci Biobehav Rev 2017; 76(Pt B): 216-34.
[28]
Thibault HB, Kurtz B, Raher MJ, et al. Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging 2010; 3(2): 157-63.
[http://dx.doi.org/10.1161/CIRCIMAGING.109.887109] [PMID: 20044514]
[29]
Bueno-Beti C, Sassi Y, Hajjar RJ, Hadri L. Pulmonary artery hypertension model in rats by monocrotaline administration. Methods Mol Biol 2018; 1816: 233-41.
[http://dx.doi.org/10.1007/978-1-4939-8597-5_18] [PMID: 29987824]
[30]
Vonk Noordegraaf A, Westerhof BE, Westerhof N. the relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol 2017; 69(2): 236-43.
[http://dx.doi.org/10.1016/j.jacc.2016.10.047] [PMID: 28081831]
[31]
Hoshikawa Y, Voelkel NF, Gesell TL, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001; 164(2): 314-8.
[http://dx.doi.org/10.1164/ajrccm.164.2.2010150] [PMID: 11463607]
[32]
Tadic M, Cuspidi C, Pencic B, Jozika L, Celic V. Relationship between right ventricular remodeling and heart rate variability in arterial hypertension. J Hypertens 2015; 33(5): 1090-7.
[http://dx.doi.org/10.1097/HJH.0000000000000511] [PMID: 25668353]
[33]
Gomez O, Okumura K, Honjo O, et al. Heart rate reduction improves biventricular function and interactions in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol 2018; 314(3): H542-51.
[PMID: 29146614]
[34]
van de Veerdonk MC, Bogaard HJ, Voelkel NF. The right ventricle and pulmonary hypertension. Heart Fail Rev 2016; 21(3): 259-71.
[http://dx.doi.org/10.1007/s10741-016-9526-y] [PMID: 26833318]
[35]
McDougall SJ, Widdop RE, Lawrence AJ. Medial prefrontal cortical integration of psychological stress in rats. Eur J Neurosci 2004; 20(9): 2430-40.
[http://dx.doi.org/10.1111/j.1460-9568.2004.03707.x] [PMID: 15525283]
[36]
Bouchery-Bardet H, Creveuil C, Bauer F, Beygui F, Champ-Rigot L, Saloux E, et al. Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis. Respir Med 2017; 132: 42-9.
[37]
Albrecht M, Henke J, Tacke S, Markert M, Guth B. Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats. BMC Vet Res 2014; 10: 198.
[http://dx.doi.org/10.1186/s12917-014-0198-3] [PMID: 25149627]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Published on: 15 September, 2020
Page: [47 - 53]
Pages: 7
DOI: 10.2174/1573398X16666200516180118
Price: $65

Article Metrics

PDF: 14